In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


Credit Designation Statement

AACR has designated this live activity for a maximum of 25.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, October 28, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 25.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

An estimated 1,806,590 new cancer cases will be diagnosed in 2020 in the United States and 606,520 people will die from the disease (1). Continued efforts are needed to identify new strategies and therapeutic options to improve patient survival and quality of life.

Immunotherapy is a promising area that takes advantage of the body’s natural defenses to fight cancer.  Scientists are discovering novel therapeutic strategies to harness the power of the immune system to specifically target tumor cells or to counteract immunosuppressive signals for improved regression and complete remission for cancer patients (2). Combination and targeted therapies are promising and active areas of study as researchers learn how to predict an individual’s response to treatment (3). Monoclonal and biscpecific antibodies and checkpoint inhibitors are being used to fight many types of cancer; with 35 antibodies and 8 checkpoint inhibitors approved by the US Food and Drug Administration (FDA; 3, 4). Adoptive cell therapy (ACT) continues to gain traction and chimeric antigen receptor (CAR)-modified T cells have shown clinical successes in hematopoietic malignancies, including the first FDA approvals of cell therapies for the treatment of cancer (3, 5).  Cancer vaccines based on tumor antigens or against immunosuppressive targets are also being developed to both treat and prevent certain cancers (3, 6). To further improve the prognosis and outcome of subsequent therapies, it is extremely important to understand the interaction of tumor cells with their microenvironment in order to hope to have the ability to predict and guide immunotherapeutic responsiveness and reveal new therapeutic targets (7). Importantly, as personalized, precision medicine becomes more prevalent, researchers and physicians can utilize imaging and artificial intelligence – to analyze and alter single cells, discover biomarkers, and monitor response – to aid more patients, faster (8). These and other new technologies have greatly enhanced our understanding of immune surveillance, vastly contributing to the development of novel immunotherapies.

To develop more effective therapies for a broader range of cancer types, it is essential to provide a venue for researchers, physician scientists, and all stakeholders, to meet, share novel findings, and have an active exchange of ideas.  The potential of immune-based therapeutics will be fully explored, with an emphasis on the tumor microenvironment and combating therapeutic resistance.  This joint meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field.  This conference will stimulate discussions and an active exchange of scientific ideas for the development of more effective therapies for a broader range of cancer types.

After participating in this CME activity, physicians should be able to:

  1. Describe the principles of cancer immunotherapy, the value of combination and checkpoint therapy, and mechanisms of new immunotherapy drugs.
  2. Articulate how combination therapy is being used in a therapeutic setting.
  3. Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth.
  4. Articulate how recent advances in adoptive cell therapy, CARs, and vaccines are contributing to personalized cancer immunotherapy.
  5. Identify mechanisms involved in the biology of vaccination.
  6. Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy.
  7. Utilize technology to aid in cancer cell characterization and immunotherapy.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants which will be disclosed at the activity.

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or [email protected].